Ecto-Calreticulin is essential for an efficient immunogenic cell death stimulation in mouse melanoma

Paola Giglio, Mara Gagliardi, Roberta Bernardini, Maurizio Mattei, Diego Cotella, Claudio Santoro, Mauro Piacentini, Marco Corazzari

Research output: Contribution to journalArticle

Abstract

Skin melanoma remains one of the most aggressive and difficult to treat human malignancy, with an increasing incidence every year. Although surgical resection represents the best therapeutic approach, this is only feasible in cases of early diagnosis. Furthermore, the established malignancy is resistant to all therapeutic strategies employed so far, resulting in an unacceptable patient survival rate. Although the immune-mediated therapeutic approaches, based on anti-PD1 or anti-CTLA4, are very promising and under clinical trial experimentation, they could conceal not yet fully emerged pitfalls such as the development of autoimmune diseases. Therefore, alternative therapeutic approaches are still under investigation, such as the immunogenic cell death (ICD) process. Here we show that the lack of calreticulin translocation onto mouse melanoma cell membrane prevents the stimulation of an effective ICD response in vivo.

Original languageEnglish
JournalGenes and Immunity
DOIs
Publication statusE-pub ahead of print - Oct 4 2018

Fingerprint

Calreticulin
Melanoma
Cell Death
Therapeutics
Autoimmune Diseases
Early Diagnosis
Neoplasms
Survival Rate
Cell Membrane
Clinical Trials
Skin
Incidence

ASJC Scopus subject areas

  • Immunology
  • Genetics
  • Genetics(clinical)

Cite this

Ecto-Calreticulin is essential for an efficient immunogenic cell death stimulation in mouse melanoma. / Giglio, Paola; Gagliardi, Mara; Bernardini, Roberta; Mattei, Maurizio; Cotella, Diego; Santoro, Claudio; Piacentini, Mauro; Corazzari, Marco.

In: Genes and Immunity, 04.10.2018.

Research output: Contribution to journalArticle

Giglio, Paola ; Gagliardi, Mara ; Bernardini, Roberta ; Mattei, Maurizio ; Cotella, Diego ; Santoro, Claudio ; Piacentini, Mauro ; Corazzari, Marco. / Ecto-Calreticulin is essential for an efficient immunogenic cell death stimulation in mouse melanoma. In: Genes and Immunity. 2018.
@article{9bbaf9cf07b94cc8b59578a60424d71e,
title = "Ecto-Calreticulin is essential for an efficient immunogenic cell death stimulation in mouse melanoma",
abstract = "Skin melanoma remains one of the most aggressive and difficult to treat human malignancy, with an increasing incidence every year. Although surgical resection represents the best therapeutic approach, this is only feasible in cases of early diagnosis. Furthermore, the established malignancy is resistant to all therapeutic strategies employed so far, resulting in an unacceptable patient survival rate. Although the immune-mediated therapeutic approaches, based on anti-PD1 or anti-CTLA4, are very promising and under clinical trial experimentation, they could conceal not yet fully emerged pitfalls such as the development of autoimmune diseases. Therefore, alternative therapeutic approaches are still under investigation, such as the immunogenic cell death (ICD) process. Here we show that the lack of calreticulin translocation onto mouse melanoma cell membrane prevents the stimulation of an effective ICD response in vivo.",
author = "Paola Giglio and Mara Gagliardi and Roberta Bernardini and Maurizio Mattei and Diego Cotella and Claudio Santoro and Mauro Piacentini and Marco Corazzari",
year = "2018",
month = "10",
day = "4",
doi = "10.1038/s41435-018-0047-7",
language = "English",
journal = "Genes and Immunity",
issn = "1466-4879",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Ecto-Calreticulin is essential for an efficient immunogenic cell death stimulation in mouse melanoma

AU - Giglio, Paola

AU - Gagliardi, Mara

AU - Bernardini, Roberta

AU - Mattei, Maurizio

AU - Cotella, Diego

AU - Santoro, Claudio

AU - Piacentini, Mauro

AU - Corazzari, Marco

PY - 2018/10/4

Y1 - 2018/10/4

N2 - Skin melanoma remains one of the most aggressive and difficult to treat human malignancy, with an increasing incidence every year. Although surgical resection represents the best therapeutic approach, this is only feasible in cases of early diagnosis. Furthermore, the established malignancy is resistant to all therapeutic strategies employed so far, resulting in an unacceptable patient survival rate. Although the immune-mediated therapeutic approaches, based on anti-PD1 or anti-CTLA4, are very promising and under clinical trial experimentation, they could conceal not yet fully emerged pitfalls such as the development of autoimmune diseases. Therefore, alternative therapeutic approaches are still under investigation, such as the immunogenic cell death (ICD) process. Here we show that the lack of calreticulin translocation onto mouse melanoma cell membrane prevents the stimulation of an effective ICD response in vivo.

AB - Skin melanoma remains one of the most aggressive and difficult to treat human malignancy, with an increasing incidence every year. Although surgical resection represents the best therapeutic approach, this is only feasible in cases of early diagnosis. Furthermore, the established malignancy is resistant to all therapeutic strategies employed so far, resulting in an unacceptable patient survival rate. Although the immune-mediated therapeutic approaches, based on anti-PD1 or anti-CTLA4, are very promising and under clinical trial experimentation, they could conceal not yet fully emerged pitfalls such as the development of autoimmune diseases. Therefore, alternative therapeutic approaches are still under investigation, such as the immunogenic cell death (ICD) process. Here we show that the lack of calreticulin translocation onto mouse melanoma cell membrane prevents the stimulation of an effective ICD response in vivo.

UR - http://www.scopus.com/inward/record.url?scp=85054363311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054363311&partnerID=8YFLogxK

U2 - 10.1038/s41435-018-0047-7

DO - 10.1038/s41435-018-0047-7

M3 - Article

AN - SCOPUS:85054363311

JO - Genes and Immunity

JF - Genes and Immunity

SN - 1466-4879

ER -